

# MARKET REPORT



Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



## Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?

## Scope

The prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medivation and Astellas expected to seek approval for their androgen receptor antagonist Xtandi (enzalutamide) for the treatment of castrate-resistant prostate cancer (CRPC) patients in the pre-chemotherapy setting.

Johnson & Johnson's Zytiga (abiraterone) – which was approved for pre-chemotherapy usage in December last year – has demonstrated that a notable commercial opportunity exists for treatment of prostate cancer at this stage. Indeed, some analysts believe that the pre-chemotherapy market could be worth up to \$5 billion in the US alone.

Furthermore, initial key opinion leader (KOL) feedback in response to top-line data from Medivation's PREVAIL study – which was released last week – would appear to suggest that Xtandi may emerge as the therapy of choice in pre-chemotherapy patients. See In Focus – Will PREVAIL data allow Medivation's Xtandi to overtake Johnson & Johnson's Zytiga in the pre-chemotherapy prostate cancer market?

Approval for the treatment of pre-chemotherapy patients is expected to significantly increase the use of Xtandi among urologists (in addition to oncologists). This population of physicians will be keen to use Xtandi, not only given its impressive overall survival (OS) and disease progression data, note KOLs, but its greater convenience; such as the lack of requirement to dose with steroids.

In addition, Xtandi's status as an androgen receptor antagonist (a familiar drug class among urologists) may prove to be useful in driving longer-term use in even earlier lines of therapy – a strategy that Johnson & Johnson is also pursuing for their next-generation prostate cancer treatment ARN-509, which was acquired from Aragon Pharmaceuticals earlier this year for a cost of up to \$1 billion.

## Purchase Reasons

This week's Physician Views poll will look to assess whether initial KOL and analyst reaction to the top-line PREVAIL data is shared by the broader urologist and oncologist populations. FirstWord is polling urologists and oncologists based in both the US and EU5 with the following questions:

Based on enzalutamide's mechanism of action (androgen receptor antagonist), how comfortable would you be in prescribing the drug on an off-label basis in the hormone ablation setting?Additional Details

**Publisher :**  
FirstWord Pharma

**Reference :**

**Number of Pages :** 0

**Report Format :** PDF

**Publisher Information :**



**FirstWord**

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data



How to Buy...Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data - can it displace Zytiga in the pre-chemotherapy prostate cancer setting?

### Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/75>

### Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$591** | Single User Price
- \$1186** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

### Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.